Compare SYBT & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SYBT | GENB |
|---|---|---|
| Founded | 1904 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2009 | N/A |
| Metric | SYBT | GENB |
|---|---|---|
| Price | $76.31 | $16.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $76.00 | $23.20 |
| AVG Volume (30 Days) | 167.3K | ★ 886.0K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $23,406,000.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $9.32 | $16.58 |
| P/E Ratio | $61.17 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $61.51 | $11.00 |
| 52 Week High | $83.83 | $17.42 |
| Indicator | SYBT | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 62.89 |
| Support Level | $68.40 | $11.73 |
| Resistance Level | N/A | $16.75 |
| Average True Range (ATR) | 1.93 | 1.02 |
| MACD | 0.19 | 0.36 |
| Stochastic Oscillator | 76.42 | 78.29 |
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.